221 related articles for article (PubMed ID: 11822752)
1. Formestane, a steroidal aromatase inhibitor after failure of non-steroidal aromatase inhibitors (anastrozole and letrozole): is a clinical benefit still achievable?
Carlini P; Frassoldati A; De Marco S; Casali A; Ruggeri EM; Nardi M; Papaldo P; Fabi A; Paoloni F; Cognetti F
Ann Oncol; 2001 Nov; 12(11):1539-43. PubMed ID: 11822752
[TBL] [Abstract][Full Text] [Related]
2. Is there a benefit by the sequence anastrozole-formestane for postmenopausal metastatic breast cancer women?
Carlini P; Ferretti G; Di Cosimo S; Colella E; Tonachella R; Romiti A; Tomao S; Frassoldati A; Papaldo P; Fabi A; Ruggeri EM; Cognetti F
J Steroid Biochem Mol Biol; 2003 Jul; 86(1):107-9. PubMed ID: 12943750
[TBL] [Abstract][Full Text] [Related]
3. Anastrozole shows evidence of activity in postmenopausal patients who have responded or stabilised on formestane therapy.
Harper-Wynne C; Coombes RC
Eur J Cancer; 1999 May; 35(5):744-6. PubMed ID: 10505035
[TBL] [Abstract][Full Text] [Related]
4. Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer.
Bertelli G; Garrone O; Merlano M; Occelli M; Bertolotti L; Castiglione F; Pepi F; Fusco O; Del Mastro L; Leonard RC
Oncology; 2005; 69(6):471-7. PubMed ID: 16410685
[TBL] [Abstract][Full Text] [Related]
5. Steroidal aromatase inhibitors in elderly patients.
Bajetta E; Zilembo N; Bichisao E; Pozzi P; Toffolatti L
Crit Rev Oncol Hematol; 2000 Feb; 33(2):137-42. PubMed ID: 10737375
[TBL] [Abstract][Full Text] [Related]
6. New aromatase inhibitors for the treatment of advanced breast cancer in postmenopausal women.
de Jong PC; Blijham GH
Neth J Med; 1999 Aug; 55(2):50-8. PubMed ID: 10474272
[TBL] [Abstract][Full Text] [Related]
7. Lessons from the use of aromatase inhibitors in the neoadjuvant setting.
Dixon JM; Love CD; Renshaw L; Bellamy C; Cameron DA; Miller WR; Leonard RC
Endocr Relat Cancer; 1999 Jun; 6(2):227-30. PubMed ID: 10731113
[TBL] [Abstract][Full Text] [Related]
8. Aromatase inhibitors and their use in the sequential setting.
Coombes RC; Harper-Wynne C; Dowsett M
Endocr Relat Cancer; 1999 Jun; 6(2):259-63. PubMed ID: 10731118
[TBL] [Abstract][Full Text] [Related]
9. Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy.
Vergote I; Robertson JF; Kleeberg U; Burton G; Osborne CK; Mauriac L; ;
Breast Cancer Res Treat; 2003 May; 79(2):207-11. PubMed ID: 12825855
[TBL] [Abstract][Full Text] [Related]
10. Aromatase inhibitors for breast cancer in postmenopausal women.
Campos SM
Oncologist; 2004; 9(2):126-36. PubMed ID: 15047917
[TBL] [Abstract][Full Text] [Related]
11. Clinical evaluation of the use of exemestane as further hormonal therapy after nonsteroidal aromatase inhibitors in postmenopausal metastatic breast cancer patients.
Carlini P; Michelotti A; Ferretti G; Ricci S; Giannarelli D; Pellegrini M; Cresti N; Di Cosimo S; Bria E; Papaldo P; Fabi A; Ruggeri EM; Milella M; Alimonti A; Salesi N; Cognetti F
Cancer Invest; 2007 Mar; 25(2):102-5. PubMed ID: 17453821
[TBL] [Abstract][Full Text] [Related]
12. [Aromatase inhibitors].
Feutrie ML; Bonneterre J
Bull Cancer; 1999 Oct; 86(10):821-7. PubMed ID: 10572233
[TBL] [Abstract][Full Text] [Related]
13. Use of aromatase inhibitors in postmenopausal women with advanced breast cancer.
Roseman BJ; Buzdar AU; Singletary SE
J Surg Oncol; 1997 Nov; 66(3):215-20. PubMed ID: 9369969
[TBL] [Abstract][Full Text] [Related]
14. Double-blind randomised trial comparing the non-steroidal aromatase inhibitors letrozole and fadrozole in postmenopausal women with advanced breast cancer.
Tominaga T; Adachi I; Sasaki Y; Tabei T; Ikeda T; Takatsuka Y; Toi M; Suwa T; Ohashi Y
Ann Oncol; 2003 Jan; 14(1):62-70. PubMed ID: 12488294
[TBL] [Abstract][Full Text] [Related]
15. An overview of the use of non-steroidal aromatase inhibitors in the treatment of breast cancer.
Buzdar A
Eur J Cancer; 2000 Sep; 36 Suppl 4():S82-4. PubMed ID: 11056331
[TBL] [Abstract][Full Text] [Related]
16. [Aromatase inhibitors: a review of clinical trials].
Kerbrat P; Lefeuvre C
Bull Cancer; 2000 Dec; 87 Spec No():31-39. PubMed ID: 11250606
[TBL] [Abstract][Full Text] [Related]
17. A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer.
Rose C
Am J Clin Oncol; 2003 Aug; 26(4):S9-16. PubMed ID: 12902872
[TBL] [Abstract][Full Text] [Related]
18. Differences between the non-steroidal aromatase inhibitors anastrozole and letrozole--of clinical importance?
Geisler J
Br J Cancer; 2011 Mar; 104(7):1059-66. PubMed ID: 21364577
[TBL] [Abstract][Full Text] [Related]
19. A randomised comparison of oestrogen suppression with anastrozole and formestane in postmenopausal patients with advanced breast cancer.
Kleeberg UR; Dowsett M; Carrion RP; Dodwell DJ; Vorobiof DA; Aparicio LA; Robertson JF
Oncology; 1997; 54 Suppl 2():19-22. PubMed ID: 9394856
[TBL] [Abstract][Full Text] [Related]
20. The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer.
Hamilton A; Piccart M
Ann Oncol; 1999 Apr; 10(4):377-84. PubMed ID: 10370778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
